-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Abbott Laboratories, Lowers Price Target to $115

Benzinga·04/17/2026 14:41:10
Listen to the news
Oppenheimer analyst Suraj Kalia maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price target from $132 to $115.